文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

留置隧道式胸腔导管治疗肝硬化难治性肝性胸腔积液:多中心研究

Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study.
PubMed 文献 · Chest · 2018-08-29
一句话结论多中心回顾性研究显示,肝硬化难治性肝性胸腔积液患者留置隧道式胸腔导管后胸腔感染风险10%、导管相关脓毒症死亡2.5%,作者认为可能是合理的临床选择但伴随显著不良事件。

该多中心回顾性研究纳入2010年1月至2016年12月八家机构的79例肝硬化难治性肝性胸腔积液患者,均留置隧道式胸腔导管(IPC),58例(73%)为姑息性置管、21例(27%)为移植前桥接。导管中位留置时间156天(范围16-1978天),8例(10%)发生胸腔感染(其中5例合并导管部位蜂窝织炎),2例(2.5%)死于导管相关脓毒症;22例(28%)因自发性胸膜固定而拔管,中位拔管时间55天(范围10-370天)。多因素分析显示年龄较大是死亡的独立预测因素(HR 1.05,P=0.01)。作者结论认为IPC可能是难治性HH患者的合理临床选择,但该病患群体中伴随显著不良事件。

要点

  • 肝硬化难治性肝性胸腔积液患者留置IPC后胸腔感染风险为10%(8/79),其中2.5%(2/79)死于导管相关脓毒症。
  • IPC置管指征:58例(73%)为姑息治疗,21例(27%)为移植前桥接;导管中位留置时间156天(范围16-1978天)。
  • 22例(28%)因自发性胸膜固定拔管,中位拔管时间55天(范围10-370天)。
  • 多因素分析显示年龄较大是死亡的独立预测因素(HR 1.05,P=0.01)。
  • 作者认为IPC可能是难治性HH患者的合理临床选择,但该病患群体中伴随显著不良事件。

适用人群与场景

  • 纳入标准:肝硬化基础上发生难治性肝性胸腔积液、并接受IPC置管的患者。
  • 研究场景:多中心(八家机构)回顾性研究,时间范围为2010年1月至2016年12月。
  • 置管指征:58例(73%)为姑息治疗,21例(27%)为移植前桥接。

红旗征与不能漏的情况

  • 胸腔感染:8例(10%)发生胸腔感染,其中5例合并导管部位蜂窝织炎。
  • 导管相关脓毒症死亡:2例(2.5%)死于导管相关脓毒症。

研究设计与关键结果

  • 研究类型:回顾性多中心研究;样本量:79例;机构数:八家;人群:肝硬化难治性肝性胸腔积液患者;干预:留置隧道式胸腔导管(IPC);主要终点:安全性与可行性。
  • 导管中位留置时间156天(范围16-1978天)。
  • 胸腔感染8例(10%),其中5例合并导管部位蜂窝织炎;导管相关脓毒症死亡2例(2.5%)。
  • 因自发性胸膜固定拔管22例(28%),中位拔管时间55天(范围10-370天)。
  • 多因素分析:年龄较大是死亡的独立预测因素(HR 1.05,P=0.01)。

证据类型、等级与局限

  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于肝硬化难治性肝性胸腔积液患者,IPC置管可能是合理的临床选择,但该病患群体中伴随显著不良事件(10%感染风险、2.5%导管相关脓毒症死亡)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The outcome of indwelling pleural catheter (IPC) use in hepatic hydrothorax (HH) is unclear. This study aimed to review the safety and feasibility of the IPC in patients with refractory HH.

METHODS: A retrospective multicenter study of patients with HH from January 2010 to December 2016 was performed. Inclusion criteria were refractory HH treated with an IPC and an underlying diagnosis of cirrhosis. Records were reviewed for patient demographics, operative reports, and laboratory values. The Kaplan-Meier method was used to estimate catheter time to removal. The Cox proportional hazard model was used to evaluate for independent predictors of pleurodesis and death.

RESULTS: Seventy-nine patients were identified from eight institutions. Indication for IPC placement was palliation in 58 patients (73%) and bridge to transplant in 21 patients (27%). The median in situ dwell time of all catheters was 156 days (range, 16-1,978 days). Eight patients (10%) were found to have pleural space infection, five of whom also had catheter-site cellulitis. Two patients (2.5%) died secondary to catheter-related sepsis. Catheter removal secondary to spontaneous pleurodesis was achieved in 22 patients (28%). Median time from catheter insertion to pleurodesis was 55 days (range, 10-370 days). Older age was an independent predictor of mortality on multivariate analysis (hazard ratio, 1.05; P = .01).

CONCLUSIONS: We present, to our knowledge, the first multicenter study examining outcomes related to IPC use in HH. Ten percent infection risk and 2.5% mortality were identified. IPC placement may be a reasonable clinical option for patients with refractory HH, but it is associated with significant adverse events in this morbid population.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Shojaee S, Rahman N, Haas K, et al. Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study. Chest. 2018. PMID: 30171863. doi:10.1016/j.chest.2018.08.1034

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。